Protein / target
Vasopressin V2 receptor
Protein at a glance
Biological role
Vasopressin receptor
Strongest disease association
Heart Failure
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
G protein-coupled receptor for arginine vasopressin, an antidiuretic that promotes renal water reabsorption.
View complete UniProt function annotationHide complete annotation
G protein-coupled receptor for arginine vasopressin, an antidiuretic that promotes renal water reabsorption (PubMed:1534149, PubMed:19440390, PubMed:33664408, PubMed:33742150). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:33664408, PubMed:33742150). AVPR2 is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:33664408, PubMed:33742150)
Subcellular location
Domains and Gene Ontology detail (25)Hide
Gene Ontology
- Cclathrin-coated endocytic vesicle membrane
- Cendocytic vesicle
- Cendoplasmic reticulum
- Cendosome
- CGolgi apparatus
- Cmembrane
- Cperinuclear region of cytoplasm
- Cplasma membrane
- Fvasopressin receptor activity
- Pactivation of adenylate cyclase activity
- Padenylate cyclase-activating G protein-coupled receptor signaling pathway
- Padenylate cyclase-modulating G protein-coupled receptor signaling pathway
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell proliferation & survival
- ·negative regulation of cell population proliferation
- ·positive regulation of cell population proliferation
G protein-coupled signalling
- ·G protein-coupled receptor for arginine vasopressin, an antidiuretic that promotes renal…
- ·adenylate cyclase-activating G protein-coupled receptor signaling pathway
- ·adenylate cyclase-modulating G protein-coupled receptor signaling pathway
- ·G protein-coupled receptor signaling pathway
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
9 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Vasopressin V2 receptor binding agent
Indicated for Renal Insufficiency
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene AVPR2
Gene-level evidence surfaced through the gene AVPR2 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (2)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
13 compounds recorded · 9 approved · 4 in clinical development
View all recorded compounds (10)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (9)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Trial status changed
Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation, A Double-blind Randomized Controlled Trial
- Label change
Label change: TERLIPRESSIN (NDA022231)
- Safety communication
Drug Safety Update: Terlipressin: new recommendations to reduce risks of respiratory failure and septic shock in patients with type 1 hepatorenal syndrome
- Label change
Label change: TERLIPRESSIN (NDA022231)
- Regulatory approval
Approval: TERLIPRESSIN (NDA022231)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.